Test for Immortality in the Reference Lab
Executive Summary
Early-stage biotechnology is hardly the most popular investment in health care these days, but Geron is doing just fine despite the fact that its clinical target, telomerase, still awaits definitive proof of value and that it has yet to clone the entire molecule.